The FeMMe Trial with Drs. Andreas Obermair and Monika Janda

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Drs. Andreas Obermair and Monika Janda to discuss the FeMMe trial. Highlights: feMMe was a randomised phase 2 trial testing LNG-IUD alone or in combination with a weight loss intervention or metformin for endometrial hyperplasia with atypia or stage 1 endometrial cancer. Overall complete pathological response at 6 month was 61%. Women with endometrial hyperplasia with atypia responded much better than women with endometrial cancer. Weight loss achieved was moderate and BMI was not associated with response – more work on weight loss interventions needed.

Metformin did not improve response – more biomarker research is needed to understand who will respond to LNG-IUD or not.